Sanofi to invest $6B in vaccines; Crucell shares jump;

> The growing wealth seen in developing nations is spurring a big increase in the worldwide demand for vaccines, and Sanofi-Aventis says it will invest more than $6 billion over the next eight years in order to meet the projected demand. Report

> Shares of Crucell jumped after the Dutch biotech named Avid BioServices as its first preapproved manufacturer in the U.S. of the PER.C6 technology for use in antibodies. Report

> Switzerland's Axentis Pharma has taken over patents for a screening tool for cystic fibrosis therapies. Axentis release

> Cell Biosciences has named Tim Harkness as its new CEO. Harkness had been CFO at Molecular Devices Corp. Report

> Many Wall Street analysts greeted the FDA's decision to reject Merck's bid to expand the use of Gardasil to 27 to 45-year-old women with a yawn. Report

> A new report by the CDC concludes that Merck's new rotavirus vaccine has made a major impact on the disease in the last two years. Vaccine report

> The obesity epidemic poses serious public health problems, but some market-watchers are looking past the cost to society for the benefits to business. Obesity report

> The FDA finds itself in the line of Congressional fire on two different issues today. One, the agency is taking some heat for the $35 million in incentive pay it handed out last fiscal year, a 29 percent hike from the year before. Report

> Merck got a trio of mixed vaccine new today. Report

> It's another blow for Roche's Avastin the U.K. The National Institute for Clinical Health and Excellence shot down the high-tech cancer med as a first-line treatment for lung and breast cancer. Report

And Finally... The Global Alliance for Vaccines and Immunization, which is backed by a host of international health groups and the Gates Foundation, is preparing a huge new initiative to vaccinate millions of children in developing nations. Report

Suggested Articles

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.